BDSI BioDelivery Sciences International Inc.

5
+0.27  (+6%)
Previous Close 4.73
Open 4.74
Price To Book 10
Market Cap 353458090
Shares 70,691,618
Volume 1,444,139
Short Ratio
Av. Daily Volume 622,588

NewsSee all news

  1. Amgen Starts Phase III Enrollment for Heart Failure Drug
  2. What's in Store for Vericel (VCEL) This Earnings Season?
  3. What's in Store for Teladoc's (TDOC) Q4 Earnings?
  4. bluebird (BLUE) Q4 Earnings Beat Estimates, Revenues Up Y/Y
  5. BioMarin (BMRN) Q4 Earnings & Sales Miss, Shares Decline

SEC filingsSee all SEC filings

  1. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19605113
  2. SC 13G - Statement of acquisition of beneficial ownership by individuals 19600939
  3. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19592582
  4. 8-K - Current report 19549322
  5. S-3/A [Amend] - Registration statement under Securities Act of 1933 19533670

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b data released December 13, 2016 - primary endpoints not met.
Clonidine gel
Painful diabetic neuropathy (PDN)
Approved June 6, 2014.
BEMA Buprenorphine/Naloxone (BNX) - BUNAVAIL
Opioid dependence
Approved October 26, 2015.
BEMA Buprenorphine
Pain

Latest News

  1. Amgen Starts Phase III Enrollment for Heart Failure Drug
  2. What's in Store for Vericel (VCEL) This Earnings Season?
  3. What's in Store for Teladoc's (TDOC) Q4 Earnings?
  4. bluebird (BLUE) Q4 Earnings Beat Estimates, Revenues Up Y/Y
  5. BioMarin (BMRN) Q4 Earnings & Sales Miss, Shares Decline
  6. BioDelivery Sciences International (BDSI) Dips More Than Broader Markets: What You Should Know
  7. Agios' Tibsovo Gets FDA Priority Review in First-Line Cancer
  8. BioDelivery Sciences to Report Fourth Quarter and Full Year 2018 Financial Results
  9. Key Factors to Know Ahead of TransEnterix (TRXC) Q4 Earnings
  10. 3 Small Biotechs to Watch as Earnings Season Winds Down
  11. Ultragenyx (RARE) Posts Narrower-Than-Expected Loss in Q4
  12. What's in Store for Sangamo (SGMO) This Earnings Season?
  13. Factors of Influence in 2019, Key Indicators and Opportunity within Procter & Gamble, Hertz Global, NN, Omnicell, BioDelivery Sciences International, and Movado Group — New Research Emphasizes Economic Growth
  14. What's in the Cards for Amarin (AMRN) This Earnings Season?
  15. Agios (AGIO) Q4 Earnings Beat, Tibsovo Sales Push Up Stock
  16. Acorda (ACOR) Q4 Earnings and Revenues Surpass Estimates
  17. Key Factors Likely to Shape CVS Health's (CVS) Q4 Earnings
  18. The Zacks Analyst Blog Highlights: BioDelivery, Cytokinetics, Celldex, Aduro and Aeterna
  19. 5 Tiny Biotech Stocks With Superb Growth Potential
  20. Can M&A Activity Drive Quest Diagnostics (DGX) Q4 Earnings?

SEC Filings

  1. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19605113
  2. SC 13G - Statement of acquisition of beneficial ownership by individuals 19600939
  3. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19592582
  4. 8-K - Current report 19549322
  5. S-3/A [Amend] - Registration statement under Securities Act of 1933 19533670
  6. 8-K - Current report 19531448
  7. S-3 - Registration statement under Securities Act of 1933 181171474
  8. 10-Q - Quarterly report [Sections 13 or 15(d)] 181170465
  9. 8-K - Current report 181169867
  10. 8-K - Current report 181144811